Evidence map›Paper›PMID 40023346›Full record

ReviewInternational journal of pharmaceutics2025

Emerging 3D printing technologies for solid oral dosage forms: Processes, materials and analytical tools for real-time assessment.

Nobel O Sierra-Vega, Muhammad Ashraf, Thomas O'Connor, Michael Kopcha, Mathew Di Prima, James Coburn, Ahmed Zidan

Abstract readReview
In one paragraph

Review in International journal of pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nobel O Sierra-VegaOffice of Pharmaceutical Quality Research, CDER, U.S. FDA, USA.
Muhammad AshrafOffice of Pharmaceutical Quality Research, CDER, U.S. FDA, USA.
Thomas O'ConnorOffice of Pharmaceutical Quality Research, CDER, U.S. FDA, USA.
Michael KopchaOffice of Pharmaceutical Quality, CDER, U.S. FDA, USA.
Mathew Di PrimaOffice of Science and Engineering Laboratories, CDRH, U.S., USA.
James CoburnFDA Office of Chief Scientists, OC, U.S. FDA, USA.
Ahmed ZidanOffice of Pharmaceutical Quality Research, CDER, U.S. FDA, USA. Electronic address: ahmed.zidan@fda.hhs.gov.

Funding

Intramural FDA HHS FD999999
6 · The paper itself

Abstract

Three-dimensional (3D) printing is an emerging technology with the potential to increase manufacturing flexibility and enable personalized drug delivery. 3D printing may form tablets using digitally controlled layer-by-layer material deposition, permitting the tailoring of solid oral dosage geometry and facile modifications of drug release profiles without requiring extensive alterations to the pharmaceutical formulation and process. The challenge to assure the quality of drugs still lies in monitoring and controlling critical steps in the 3D printing process. Optimizing an 3D printing process requires a comprehensive understanding of the critical process parameters, material attributes and their impact on the performance of 3D-printed tablets. This review focuses on recent advances in 3D printing technologies for solid oral dosage forms, emphasizing critical process parameters and material attributes that may be considered for optimizing printing processes and enhancing the quality of printed tablets. Additionally, this review explores real-time analytical tools and the crucial considerations for ensuring the performance of building materials, printing processes, and manufactured solid drug products. This review contributes to the ongoing discourse on harnessing the potential of 3D printing in the pharmaceutical field while emphasizing the imperative need for quality assurance throughout additive manufacturing processes.

Indexed as

Printing, Three-DimensionalTechnology, PharmaceuticalAdministration, OralDrug CompoundingDrug Delivery SystemsDrug LiberationHumansTabletsTablets3D printingAdditive manufacturingEmerging technologyProcess analytical technologyProcess parametersQuality attributes

Identifiers

PMID40023346
PMCPMC12902829

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.